Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dapagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
Details : Dapagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 13, 2025
Lead Product(s) : Dapagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies
Details : Nov1601 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2019
Lead Product(s) : Aripiprazole
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aripiprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 17, 2015
Lead Product(s) : Aripiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
